Anti-nucleosome and anti-chromatin antibodies are present in active systemic lupus erythematosus but not in the cutaneous form of the disease

Abstract

The objective of this study is to investigate the presence of anti-nucleosome (anti-NCS) and anti-chromatin (anti-CRT) antibodies in patients with cutaneous lupus erythematosus (CLE) compared with active and inactive systemic lupus erythematosus (SLE). A total of 154 subjects were evaluated: 54 patients presenting CLE, 66 patients with active SLE and 34 with inactive SLE. Lupus activity was assessed using the disease activity index (SLEDAI). Anti-NCS and anti-CRT antibodies were detected by enzyme-linked immunosorbent assay (ELISA). Only one of 54 patients with CLE tested positive for both anti-NCS and anti-CRT antibodies. The prevalence of anti-CRT antibodies was significantly higher in active SLE (84.8%) when compared with inactive SLE (26.4%) and CLE (1.8%) (P < 0.001). Anti-NCS antibodies were also more prevalent in active SLE patients (74.2%) than inactive SLE (11.7%) and CLE patients (1.8%) (P < 0.001). The presence of anti-CRT and anti-NCS antibodies was correlated to disease activity in patients with SLE (r = 0.4937, r = 0.5621, respectively). Furthermore, the detection of both antibodies was correlated with disease activity in patients with SLE who tested negative for anti-dsDNA antibodies (r = 0.4754 for anti-NCS and r = 0.4281 for anti-CRT). The presence of these two auto-antibodies was strongly associated with renal damage in patients with SLE (OR = 13.1, for anti-CRT antibodies and OR = 25.83, for anti-NCS antibodies). The anti-NCS and anti-CRT antibodies were not found in CLE. In patients with SLE, there is a correlation of these antibodies with disease activity and active nephritis. When compared with anti-dsDNA antibodies, anti-NCS and anti-CRT antibodies were more sensitive in detecting disease activity and kidney damage in lupus patients.

Keywords

anti-chromatin anti-nucleosome cutaneous lupus SLEDAI systemic lupus erythematosus

Get full access to this article

View all access options for this article.

References

1 Goodfiel MJD Jones SK Veale DJ . The connective tissue diseases. In: T Burns S Brethnach N Cox C Griffiths , (eds) Rook’s textbook of dermatology. 7th ed. Blackwell; 2004. p. 1–70.

2 Meller S Winterberg F Gilliet M . Ultraviolet radiation-induced injury, chemokines, and leukocyte recruitment: an amplification cycle triggering cutaneous lupus erythematosus. Arthritis Rheum 2005; 52: 1504–1516.

3 Kunh A Herrmann M Kleber S . Accumulation of apoptotic cells in the epidermis of patients with cutaneous lupus erythematosus after ultraviolet irradiation. Arthritis Rheum 2006; 54: 939–950.

4 Reefman E De Jong MC Kuiper H . Is disturbed clearance of apoptotic keratinocytes responsible for UVB-induced inflammatory skin lesions in systemic lupus erythematosus. Arthritis Res Ther 2006; 8: R156.

5 Baima B Sticherling M . Apoptosis in different cutaneous manifestations of lupus erythematosus. Br J Dermatol 2001; 144: 958–966.

6 Merovach D Zhou JL Song X Elkon KB . Systemic exposure to irradiated apoptotic cells induces autoantibody production. J Exp Med 1998; 188: 387–392.

7 Radic M Marion T Monestier M . Nucleosomes are exposed at the cell surface in apoptosis. J Immunol 2004; 172: 6692–6700.

8 Stollar BD Stephenson F . Apoptosis and nucleosomes. Lupus 2002; 11: 787–789.

9 Mohan C Adams S Stanik V Datta SK . Nucleosome: a major immunogen for pathogenic autoantibody-inducing T cells of lupus. J Exp Med 1993; 177: 1367–1381.

10.

10 Berden JH . Role of nucleosomes for induction and glomerular binding of autoantibodies in lupus nephritis. Curr Opin Nephrol Hypertens 1999; 8: 299–306.

11.

11 Grootscholten C Dieker JW Mcgrath FD . A prospective study of anti-chromatin and anti-C1q autoantibodies in patients with proliferative lupus nephritis treated with cyclophosphamide pulses or azathioprine/methylprednisolone. Ann Rheum Dis 2007; 66: 693–696.

12.

12 Hochberg MC . Updating the American College of Rheumatology Revised Criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725 (letter).

13.

13 Gladman DD Urowitz MB Goldsmith CH . The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum 1997; 40: 809–813.

14.

14 Magalhães MB da Silva LM Voltarelli JC Donadi EA Louzada-Junior P . Lymphocytotoxic antibodies in systemic lupus erythematosus are associated with disease activity irrespective of the presence of neuropsychiatric manifestations. Scand J Rheumatol 2007; 36: 442–447.

15.

15 Gómez-Puerta JA Burlingame RW Cervera R . Antichromatin (antinucleosome) antibodies. Lupus 2006; 15: 408–411.

16.

16 Simón JA Cabiedes J Ortiz E Alcocer-Varela J Sánchez-Guerrero J . Anti-nucleosome antibodies in patients with systemic lupus erythematosus of recent onset. Potential utility as a diagnostic tool and disease activity marker. Rheumatology 2004; 43: 2002–2004.

17.

17 Ghillani-Dalbin P Amoura Z Cacoub P . Testing for anti-nucleosome antibodies in daily practice: a monocentric evaluation in 1696 patients. Lúpus 2003; 12: 833–837.

18.

18 Chabre H Amoura Z Piette JC Godeau P Bach JF Koutouzov S . Presence of nucleosome-restricted antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 1995; 38: 1485–1491.

19.

19 Burlingame RW . The clinical utility of anti-histone antibodies: autoantibodies reactive with chromatin in systemic lupus erythematosus and drug-induced lupus. Clin Lab Med 1997; 17: 367–378.

20.

20 Rahman A Hiepe F . Anti-DNA antibodies-overview of assays and clinical correlations. Lupus 2002; 11: 770–773.

21.

21 Servais G Daens S Guillaume MP Cumps J Duchateau J Peretz A . Diagnostic specificities and sensitivities of anti-dsDNA, anti-membrane DNA and anti-nucleosome autoantibodies. Scan J Clin Lab Invest 2001; 61: 61–67.

22.

22 Wallace DJ Pistiner M Nessim S Metzger AL Klinenberg JR . Cutaneous lupus erythematosus without systemic lupus erythematosus: clinical and laboratory features. Semin Arthritis Rheum 1992; 21: 221–226.

23.

23 Tebbe B Mansmann U Wollina U . Markers in cutaneous lupus erythematosus indicating systemic involvement. a multicenter study on 296 patients. Acta Derm Venereol 1997; 77: 305–308.

24.

24 Tebbe B Orfanos CE . Anticardiolipin antibodies in cutaneous lupus erythematosus. Incidence and importance as a marker of vascular symptoms. Hautarzt 1992; 43: 130–133.

25.

25 Amoura Z Koutouzov S Chabre H . Presence of antinucleosome autoantibodies in a restricted set of connective tissue diseases. Arthritis Rheum 2000; 43: 76–84.

26.

26 Julkunen H Salonen EM Walle TK Miettinen A . Anti-nucleosome antibodies in the diagnosis of systemic lupus erythematosus. Scand J Rheumatol 2005; 2: 122–124.

27.

27 Ng KP Masson JJ Rahman A Isenberg DA . Association of anti-nucleosome antibodies with disease flare in serologically active clinically quiescent patients with systemic lupus erythematosus. Arthritis Rheum 2006; 55: 900–904.

28.

28 Su Y Jia RL Han L Li ZG . Role of anti-nucleosome antibody in the diagnosis of systemic lupus erythematosus. Clin Immunol 2007; 122: 115–120.

29.

29 Linnik MD Hu JZ Heilbrunn KR Strand V Hurley FL Joh T . LJP 394 Investigator Consortium. Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus. Arthritis Rheum 2005; 52: 1129–1137.

30.

30 Isenberg D . Anti-dsDNA antibodies: still a useful criterion for patients with systemic lupus erythematosus. Lupus 2004; 13: 881–885.

31.

31 Min DJ Kim SJ Park SH . Anti-nucleosome antibody: significance in lupus patients lacking anti-double stranded-DNA antibody. Clin Exp Rheumatol 2002; 20: 13–18.

32.

32 Adrianzén-Gutiérrez OA Koutouzov S Mota RMS . Diagnostic value of anti-nucleosome antibodies in the assessment of disease activity of systemic lupus erythematosus: a prospective study comparing anti-nucleosome with anti-dsDNA antibodies. J Rheumatol 2006; 3: 1538–1544.

33.

33 Saisoong S Eiam-Ong S Hanvivatvong O . Correlations between anti-nucleosome antibodies and anti-double-stranded DNA antibodies, C3, C4, and clinical activity in lupus patients. Clin Exp Rheumatol 2006; 24: 51–58.

34.

34 Amoura Z Koutouzov S Piette JC . The role of nucleosomes in lupus. Curr Opin Rheumatol 2000; 12: 369–373.

35.

35 Amoura Z Chabre H Koutouzov S . Nucleosome-restricted antibodies are detected before anti-dsDNA and/or anti-histone antibodies in serum of MRL-Mp Ipr/Ipr and +/+mice, and are present in kidney eluates of lupus mice with proteinuria. Arthritis Rheum 1994; 37: 568–577.

36.

36 Suenaga R Mitamura K Abdou NI . Isolation of anti-nucleosome antibodies from the plasma of lupus nephritis patients. Clin Rheumatol 1998; 17: 189–194.

37.

37 Van Bavel CC Van Der Vlag J Berden JH . Glomerular apoptotic nucleosomes are central target structures for nephritogenic antibodies in human SLE nephritis. Kidney Int 2007; 71: 664–672.